LCK and myelofibrosis: We analyzed theposes of the top de novo moleculeagainst JAK2 and LCK using PLIP, a 3D interaction profiler.99 For comparison, we also analyzed the interactionsof two example inhibitors (shown in Figure 12) for which crystal structures were known.The first inhibitor, ruxolitinib, is a JAK2-targeting drug approvedto treat myelofibrosis, a rare type of bone marrow cancer.